Benzodiazepines could significantly increase flu risk

During 2014, the three most widely used hypnotic and anxiolytic benzodiazepines (diazepam, temazepam and lorazepam) were dispensed over eight million times in England, according to the HSCIC. Zopiclone accounted for a further 5.7m items. Now new research suggests that benzodiazepines may quadruple the likelihood of pneumonia and increase mortality more than 20-fold in people with influenza-like illness (ILI), Pharmacoepidemiology and Drug Safety reports.

Recent studies have raise concerns that benzodiazepines may undermine the immune response to infection so researchers decided to collect data on 804,051 patients from the UK’s Clinical Practice Research Datalink for 30 days from ILI diagnosis. They defined ‘current use’ as a prescription in the month before ILI diagnosis.

The median age at ILI diagnosis was 25 years. During the 30-day follow-up, 0.14 per cent of the ILI patients developed pneumonia and 0.09 per cent died. After adjusting for confounders, current benzodiazepine use increased the risk of ILI-related pneumonia more than four-fold (hazard ratio [HR] 4.24) and mortality almost 21-fold (adjusted HR 20.69).

Current temazepam use increased the risks five and 20-fold respectively (HR 5.19 and 19.56). The doubling in ILI-related pneumonia among current zopiclone users (HR 1.97) did not reach statistical significance but current zopiclone use was associated with an 11-fold increase in ILI-related deaths (HR 10.86).

The authors advocate “a cautionary approach to prescribing benzodiazepine[s] … in people known to be at increased risk of pneumonia or mortality”.

(DOI: 10.1002/pds.4028)

Latest discussions

  1. Pre reg exams

    Thanks for your comments both - Richard ...

  2. Pre reg exams

    Having been qualified just over 40 years...

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.